Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 11;26(9):1107–1124. doi: 10.1177/24725552211020668

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 1. — Establishing a high-throughput assay for automated seeding, treatment, and analysis of prostate cancer organoids. (A) Prostate cancer tissue is acquired from patients and used to establish serially transplantable patient-derived xenografts (PDXs). PDX tissue is then digested and cultured in Matrigel as organoids. (B) Organoids are robotically seeded in 384-well plates and monitored at different intervals using live-cell brightfield microscopy. Drug treatment started at 8 d in culture and concluded at day 21. (C) After treatment, live-cell imaging followed by endpoint CTG measurements were performed. Microscopy images were segmented and quantified using CellProfiler software. CTG and imaging data were analyzed using R software. BF = brightfield microscopy; CTG = CellTiter-Glo; PDX = patient-derived xenograft.